Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

What Is the Role for Antidepressants in Bipolar Disorder?

Source: Recent Advances in the Management of Bipolar Depression
Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder.
Joseph F. Goldberg, MD
Greg W. Mattingly, MD
Released: October 5, 2021

In this episode, Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder. They review use of newer antidepressants (eg, vortioxetine, vilazodone) for bipolar depression despite lack of large, formal studies for that indication, the safety/efficacy of antidepressants for bipolar II vs bipolar I, antidepressant monotherapy in bipolar II depression, ketamine/esketamine for bipolar depression, and discuss the role for an antidepressant for bipolar depression in the absence of mixed features.

Information on this Educational Activity

Faculty

Joseph F. Goldberg, MD

Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Joseph Goldberg, MD, has disclosed that he has received consulting fees from BioXcel, Lundbeck, Otsuka, and Sunovion and fees for non-CME/CE services from Allergan, Intercellular Therapies, and Sunovion.
Greg W. Mattingly, MD

Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
Midwest Research Group
St. Louis, Missouri

Greg Mattingly, MD, has disclosed that he has received consulting fees from AbbVie, Acadia, Alkermes, Axsome, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Otsuka, Redax, Roche, Rhodes, Sage, Shire, Sunovion, Supernus, Takeda, Teva, and Trispharma; funds for research support from AbbVie, Acadia, Alkermes, Avanir, Axsome, Boehringer Ingelheim, Emalex, Janssen, Medgenics, NLS-1 Pharma AG, Redax, Roche, Sage, Shire, Sunovion, Supernus, Takeda, and Teva; and fees for non-CME/CE services from AbbVie, Alkermes, Eisai, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, and Trispharma.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Intra-Cellular Therapies, Inc.

Related Content

Experts in psychiatry discuss treatment strategies for the bipolar depression spectrum, from Clinical Care Options (CCO)

Vladimir Maletic, MD Greg W. Mattingly, MD Released: October 6, 2022

Accurate diagnosis and treatment selection in a patient with bipolar depression patient case from Clinical Care Options (CCO)

Leslie Citrome, MD, MPH
Program Director Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credits Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: September 30, 2022 Expired: September 29, 2023

Interactive case study demonstrating TD diagnosis and management in patients with primary mood disorders, from Clinical Care Options (CCO)

person default Jacob Ballon, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credits Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: September 30, 2022 Expired: September 29, 2023

A psychiatrist interviews a patient with tardive dyskinesia to provide insights on the disease from the patient perspective from Clinical Care Options (CCO)

Joseph P. McEvoy, MD Released: September 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings